NPL

Summary

NPL (N-acetylneuraminate pyruvate lyase, HGNC:16781) is a protein-coding gene on chromosome 1q25.3, encoding N-acetylneuraminate lyase (Q9BXD5). Catalyzes the cleavage of N-acetylneuraminic acid (sialic acid) to form pyruvate and N-acetylmannosamine via a Schiff base intermediate.

This gene encodes a member of the N-acetylneuraminate lyase sub-family of (beta/alpha)(8)-barrel enzymes. N-acetylneuraminate lyases regulate cellular concentrations of N-acetyl-neuraminic acid (sialic acid) by mediating the reversible conversion of sialic acid into N-acetylmannosamine and pyruvate. A pseudogene of this gene is located on the short arm of chromosome 2. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 80896 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 58 total
• MANE Select transcript: NM_030769

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16781
Approved symbol	NPL
Name	N-acetylneuraminate pyruvate lyase
Location	1q25.3
Locus type	gene with protein product
Status	Approved
Aliases	NPL1, DHDPS1
Ensembl gene	ENSG00000135838
Ensembl biotype	protein_coding
OMIM	611412
Entrez	80896

Gene structure

Transcript identifiers

Ensembl transcripts: 45 — 39 protein_coding, 6 protein_coding_CDS_not_defined

ENST00000258317, ENST00000367552, ENST00000367553, ENST00000367554, ENST00000367555, ENST00000460179, ENST00000460690, ENST00000463899, ENST00000471010, ENST00000479721, ENST00000488424, ENST00000614468, ENST00000879498, ENST00000879499, ENST00000879500, ENST00000879501, ENST00000879502, ENST00000879503, ENST00000879504, ENST00000879505, ENST00000879506, ENST00000879507, ENST00000879508, ENST00000879509, ENST00000879510, ENST00000879511, ENST00000879512, ENST00000879513, ENST00000879514, ENST00000879515, ENST00000879516, ENST00000879517, ENST00000879518, ENST00000879519, ENST00000913310, ENST00000949073, ENST00000949074, ENST00000949075, ENST00000949076, ENST00000949077, ENST00000949078, ENST00000949079, ENST00000949080, ENST00000949081, ENST00000949082

RefSeq mRNA: 5 — MANE Select: NM_030769 NM_001200050, NM_001200051, NM_001200052, NM_001200056, NM_030769

CCDS: CCDS1350, CCDS55666, CCDS55667, CCDS72990

Canonical transcript exons

ENST00000367553 — 13 exons

Exon	Start	End
ENSE00001445014	182792232	182792286
ENSE00001926869	182789773	182789805
ENSE00002297266	182828724	182830384
ENSE00003460025	182825781	182825820
ENSE00003466245	182816714	182816806
ENSE00003535241	182803698	182803771
ENSE00003554575	182806145	182806232
ENSE00003567390	182818541	182818689
ENSE00003570256	182812156	182812213
ENSE00003615333	182818813	182818859
ENSE00003630071	182814783	182814858
ENSE00003634847	182794356	182794439
ENSE00003665852	182822115	182822199

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 97.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.1140 / max 1758.7315, expressed in 1262 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
7045	29.1140	1262

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	97.87	gold quality
mononuclear cell	CL:0000842	97.26	gold quality
leukocyte	CL:0000738	96.95	gold quality
blood	UBERON:0000178	95.73	gold quality
granulocyte	CL:0000094	91.67	gold quality
spleen	UBERON:0002106	91.60	gold quality
sperm	CL:0000019	89.82	silver quality
gall bladder	UBERON:0002110	88.70	gold quality
right lung	UBERON:0002167	88.52	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.26	gold quality
adult mammalian kidney	UBERON:0000082	88.13	gold quality
secondary oocyte	CL:0000655	88.08	gold quality
lymph node	UBERON:0000029	87.89	gold quality
gingival epithelium	UBERON:0001949	87.82	silver quality
nephron tubule	UBERON:0001231	87.38	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.18	gold quality
bone marrow	UBERON:0002371	87.15	gold quality
trabecular bone tissue	UBERON:0002483	87.10	gold quality
caudate nucleus	UBERON:0001873	87.04	gold quality
upper leg skin	UBERON:0004262	86.88	gold quality
superficial temporal artery	UBERON:0001614	86.86	gold quality
upper lobe of left lung	UBERON:0008952	86.77	gold quality
placenta	UBERON:0001987	86.76	gold quality
upper lobe of lung	UBERON:0008948	86.75	gold quality
male germ cell	CL:0000015	86.40	silver quality
spinal cord	UBERON:0002240	86.22	gold quality
visceral pleura	UBERON:0002401	86.05	gold quality
gingiva	UBERON:0001828	85.91	silver quality
parietal pleura	UBERON:0002400	85.53	gold quality
lower lobe of lung	UBERON:0008949	85.41	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	55.08
E-MTAB-6678	yes	39.45
E-HCAD-25	yes	24.66
E-CURD-112	yes	14.95
E-MTAB-9388	yes	7.76
E-HCAD-10	no	2.12
E-MTAB-9467	no	0.91
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

87 targeting NPL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-664B-3P	99.84	71.65	3590

Literature-anchored findings (GeneRIF, showing 2)

• an NPL splice variant is mainly expressed in human liver, kidney and peripheral blood leukocytes (PMID:16147865)
• 3D structure model of N-acetylneuraminate lyase from human (hNAL, EC 4.1.3.3) was created and refined (PMID:19057931)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	npl	ENSDARG00000009390
mus_musculus	Npl	ENSMUSG00000042684
rattus_norvegicus	Npl	ENSRNOG00000002775

Paralogs (1): HOGA1 (ENSG00000241935)

Protein

Protein identifiers

N-acetylneuraminate lyase — Q9BXD5 (reviewed: Q9BXD5)

Alternative names: N-acetylneuraminate pyruvate-lyase, N-acetylneuraminic acid aldolase, Sialate lyase, Sialate-pyruvate lyase, Sialic acid aldolase, Sialic acid lyase

All UniProt accessions (2): A0A087WZ70, Q9BXD5

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the cleavage of N-acetylneuraminic acid (sialic acid) to form pyruvate and N-acetylmannosamine via a Schiff base intermediate. It prevents sialic acids from being recycled and returning to the cell surface. Involved in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway. Although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded.

Subunit / interactions. Homotetramer.

Subcellular location. Cytoplasm.

Tissue specificity. Isoform 2 is expressed in placenta, liver, kidney, pancreas, spleen, thymus, ovary, small intestine and peripheral blood leukocyte.

Pathway. Amino-sugar metabolism; N-acetylneuraminate degradation.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the DapA family. NanA subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9BXD5-1	1	yes
Q9BXD5-2	2
Q9BXD5-3	3
Q9BXD5-4	4
Q9BXD5-5	5

RefSeq proteins (5): NP_001186979, NP_001186980, NP_001186981, NP_001186985, NP_110396* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002220	DapA-like	Family
IPR005264	NanA	Family
IPR013785	Aldolase_TIM	Homologous_superfamily

Pfam: PF00701

Enzyme classification (BRENDA):

• EC 4.1.3.3 — N-acetylneuraminate lyase (BRENDA: 30 organisms, 144 substrates, 77 inhibitors, 161 Km, 114 kcat entries)

Substrate kinetics (BRENDA)

21 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
N-ACETYLNEURAMINIC ACID	0.4–1100	34
N-ACETYLNEURAMINATE	0.013–87.7	30
N-ACETYL-D-MANNOSAMINE	6.9–3200	15
N-ACETYL-D-NEURAMINIC ACID	2.1–59.5	14
PYRUVATE	0.5–72.4	13
(5R,6R)-7-(DIPROPYLAMINO)-4,5,6-TRIHYDROXY-2,7-D	0.2–11	10
(2S,4S,5R,6R)-5-(ACETYLAMINO)-6-[(DIPROPYLAMINO)	0.35–10.6	6
D-3-DEOXY-MANNO-2-OCTULOSONIC ACID	3.5–14.5	6
L-3-DEOXY-MANNO-2-OCTULOSONIC ACID	2.4–14.1	6
N-ACETYL-L-NEURAMINIC ACID	4.4–369.4	4
N-GLYCOLYLNEURAMINIC ACID	2.2–4.6	4
(2R,3R,4R)-6-[(AMINOOXY)CARBONYL]-3,4,6-TRIHYDRO	0.39–11	2
SIALIC ACID	4.4–38	2
N-ACETYL-4-O-ACETYLNEURAMINIC ACID	12.5	1
N-ACETYL-7-O-ACETYLNEURAMINIC ACID	4.5	1

Catalyzed reactions (Rhea), 1 shown:

• aceneuramate = aldehydo-N-acetyl-D-mannosamine + pyruvate (RHEA:23296)

UniProt features (46 total): helix 16, strand 9, binding site 7, splice variant 5, sequence conflict 4, active site 2, turn 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6ARH	X-RAY DIFFRACTION	1.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXD5-F1	93.61	0.90

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 143 (proton donor); 173 (schiff-base intermediate with substrate)

Ligand- & substrate-binding residues (7): 51; 52; 175; 199; 201; 202; 218

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-4085001	Sialic acid metabolism

MSigDB gene sets: 224 (showing top): MODULE_418, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, GOBP_AMIDE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_AMINO_SUGAR_CATABOLIC_PROCESS, GOBP_AMINO_SUGAR_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GATA1_03, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, BROWN_MYELOID_CELL_DEVELOPMENT_DN

GO Biological Process (2): carbohydrate metabolic process (GO:0005975), N-acetylneuraminate catabolic process (GO:0019262)

GO Molecular Function (4): N-acetylneuraminate lyase activity (GO:0008747), identical protein binding (GO:0042802), protein binding (GO:0005515), lyase activity (GO:0016829)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Synthesis of substrates in N-glycan biosythesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
primary metabolic process	1
N-acetylneuraminate metabolic process	1
amino sugar catabolic process	1
carboxylic acid catabolic process	1
oxo-acid-lyase activity	1
protein binding	1
binding	1
catalytic activity	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1362 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NPL	CMAS	Q8NFW8	524
NPL	ACR	P10323	480
NPL	GNE	Q9Y223	465
NPL	NANP	Q8TBE9	456
NPL	NANS	Q9NR45	445
NPL	ST8SIA5	O15466	445
NPL	ZBTB8B	Q8NAP8	418
NPL	PRAP1	Q96NZ9	405
NPL	SLC35A1	P78382	399
NPL	SLC17A5	Q9NRA2	372
NPL	NEU1	Q99519	362
NPL	RENBP	P51606	356
NPL	MBOAT1	Q6ZNC8	355
NPL	POLN	Q7Z5Q5	355
NPL	PRKRIP1	Q9H875	355

IntAct

11 interactions, top by confidence:

A	B	Type	Score
NPL	NPL	psi-mi:“MI:0915”(physical association)	0.670
NPL	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
NTAQ1	NPL	psi-mi:“MI:0915”(physical association)	0.560
NPL	PEG10	psi-mi:“MI:0915”(physical association)	0.400
NPL	CFAP418	psi-mi:“MI:0915”(physical association)	0.370
NPL	ODR4	psi-mi:“MI:0914”(association)	0.350
NPL	NPL	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (13): NPL (Two-hybrid), NPL (Two-hybrid), PEG10 (Affinity Capture-MS), QPRT (Affinity Capture-MS), NPL (Proximity Label-MS), NPL (Two-hybrid), PEG10 (Affinity Capture-MS), UFSP2 (Affinity Capture-MS), C1orf27 (Affinity Capture-MS), NPL (Proximity Label-MS), NPL (Proximity Label-MS), NPL (Proximity Label-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A4IT57, A8NEP3, B0B8N1, B0BAB0, B0BBG3, B0SBH6, B0SJ25, B3EK39, B4GP48, B4S3A5, G5EDZ2, O13831, O34873, P00480, P0CD74, P16578, P54724, Q11185, Q1RMS2, Q254V9, Q25566, Q29BL3, Q29RY9, Q3B8E8, Q3KL39, Q5F3Z1, Q5L789, Q5M8W9, Q5M905, Q5RDY1, Q5XGL6, Q5XGL8, Q5ZKD4, Q66H59, Q6MD01, Q6MEB3, Q6NY77, Q6NYR8, Q7SZS2, Q822T2

Diamond homologs: A1AGB9, A1ATI8, A3N352, A4WF38, A5GD89, A5IPI2, A6QDU7, A6TY99, A7B555, A7WXZ2, A7Z4U8, A7ZSB8, A8A535, A8AQB6, A8YZD9, A9MNY6, A9N833, B0BSI2, B0R3D6, B0UTI7, B1IQQ4, B1LGJ0, B1XHJ8, B2U1V9, B3E936, B3EMS4, B3GZ05, B3QUT2, B4T750, B4TJR3, B4TWJ0, B5BGP5, B5EGX4, B5F7J9, B5FIR8, B5R0L2, B5RET7, B5YSV2, B6I1U3, B7LHT3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2096 predictions. Top by Δscore:

Variant	Effect	Δscore
1:182803686:C:G	acceptor_gain	1.0000
1:182803687:A:AG	acceptor_gain	1.0000
1:182803688:T:G	acceptor_gain	1.0000
1:182803696:A:AG	acceptor_gain	1.0000
1:182803697:G:GG	acceptor_gain	1.0000
1:182803697:GA:G	acceptor_gain	1.0000
1:182814778:TAAA:T	acceptor_loss	1.0000
1:182814779:A:AG	acceptor_gain	1.0000
1:182814779:AAAG:A	acceptor_gain	1.0000
1:182814780:A:G	acceptor_gain	1.0000
1:182814781:A:AG	acceptor_gain	1.0000
1:182814782:G:GG	acceptor_gain	1.0000
1:182814782:GGCCC:G	acceptor_gain	1.0000
1:182814856:AAG:A	donor_gain	1.0000
1:182814856:AAGGT:A	donor_loss	1.0000
1:182814857:AG:A	donor_gain	1.0000
1:182814857:AGGTA:A	donor_loss	1.0000
1:182814858:GG:G	donor_gain	1.0000
1:182814858:GGTA:G	donor_loss	1.0000
1:182814859:G:GA	donor_loss	1.0000
1:182814859:G:GG	donor_gain	1.0000
1:182816803:AAGAG:A	donor_loss	1.0000
1:182816804:AGA:A	donor_gain	1.0000
1:182816805:GA:G	donor_gain	1.0000
1:182816805:GAG:G	donor_gain	1.0000
1:182816806:AGTA:A	donor_loss	1.0000
1:182816807:G:GG	donor_gain	1.0000
1:182816808:T:A	donor_loss	1.0000
1:182818787:A:G	acceptor_gain	1.0000
1:182825779:A:AG	acceptor_gain	1.0000

AlphaMissense

2097 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:182806210:T:A	W70R	0.997
1:182806210:T:C	W70R	0.997
1:182818603:T:C	F174L	0.997
1:182818605:C:A	F174L	0.997
1:182818605:C:G	F174L	0.997
1:182818606:A:C	S175R	0.997
1:182818608:T:A	S175R	0.997
1:182818608:T:G	S175R	0.997
1:182822124:C:A	N221K	0.997
1:182822124:C:G	N221K	0.997
1:182828746:A:C	K267N	0.997
1:182828746:A:T	K267N	0.997
1:182806190:G:C	R63P	0.996
1:182818602:A:C	K173N	0.995
1:182818602:A:T	K173N	0.995
1:182818685:A:T	D201V	0.995
1:182828745:A:T	K267I	0.995
1:182818858:A:C	S218R	0.994
1:182822115:T:A	S218R	0.994
1:182822115:T:G	S218R	0.994
1:182794412:C:A	A14E	0.993
1:182806201:G:C	A67P	0.993
1:182814792:G:C	A100P	0.993
1:182818684:G:C	D201H	0.993
1:182818685:A:C	D201A	0.993
1:182818856:G:A	G217D	0.993
1:182806145:T:A	V48E	0.992
1:182806189:C:A	R63S	0.992
1:182814819:G:C	A109P	0.992
1:182818679:G:A	G199E	0.992

dbSNP variants (sampled 300 via entrez): RS1000032560 (1:182798405 T>G), RS1000082819 (1:182807604 T>A,C), RS1000112665 (1:182791158 T>C), RS1000162585 (1:182788756 T>C), RS1000176560 (1:182791978 T>C), RS1000215918 (1:182788214 C>A), RS1000490152 (1:182795020 T>C), RS1000531507 (1:182826852 C>T), RS1000575940 (1:182820483 G>C,T), RS1000633234 (1:182799859 G>A), RS1000684806 (1:182827837 A>C), RS1000705448 (1:182814228 C>G), RS1000721914 (1:182806522 G>A), RS1000881048 (1:182799880 C>A,T), RS1001076226 (1:182820659 T>C)

Disease associations

OMIM: gene MIM:611412 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004403_7	Bone fracture in osteoporosis	7.000000e-06
GCST007565_110	Morning person	1.000000e-28
GCST012020_241	Serum metabolite levels	2.000000e-18

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008328	chronotype measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
Endosulfan	decreases expression	3
bisphenol A	increases methylation, decreases expression, decreases methylation	2
Cyclosporine	increases expression, decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
Particulate Matter	decreases expression	2
2,4,6-tribromophenol	increases expression	1
bufotalin	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
trichostatin A	increases expression	1
sodium bichromate	decreases expression	1
butyraldehyde	increases expression	1
tetrabromobisphenol A	increases expression	1
perfluorooctanoic acid	increases expression	1
nickel sulfate	decreases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	affects response to substance	1
Sunitinib	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TA92	HAP1 NPL (-) 1	Cancer cell line	Male
CVCL_XR05	HAP1 NPL (-) 2	Cancer cell line	Male
CVCL_XR06	HAP1 NPL (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.